Integrated Analysis of Gut Microbiota Dysbiosis and microRNA-155/microRNA-20a Expression Across Multiple Sclerosis Disease subtypes: Comparison with Controls
This study demonstrates that gut microbiota dysbiosis and circulating miR-155/miR-20a expression profiles are distinct across Multiple Sclerosis subtypes, with secondary progressive MS showing the most severe alterations, and that integrated microbial-miRNA signatures offer high diagnostic accuracy for discriminating clinical phenotypes from controls.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Multiple sclerosis is a condition where the body's own immune system mistakenly attacks the protective coating around nerve fibers in the brain and spinal cord. This damage disrupts the signals that tell muscles how to move and how to feel, leading to a wide range of symptoms that can vary greatly from person to person. While doctors know that genetics and the environment play a role in who gets the disease, the exact reasons why it starts and how it changes over time remain a mystery. In recent years, scientists have begun to look closely at the trillions of tiny bacteria living in the human gut, known as the gut microbiota. These microbes are not just passengers; they interact constantly with the immune system, helping to train it to know the difference between friend and foe. Alongside these bacteria, the body uses tiny molecules called microRNAs to act as dimmer switches for genes, turning the production of certain proteins up or down to control inflammation. The big question for researchers has been whether the mix of bacteria in the gut and the activity of these genetic switches are linked to the different forms of multiple sclerosis, and if looking at both together could help doctors tell the different types of the disease apart.
A team of researchers in Iran set out to answer this by studying 240 people, divided into six equal groups. Four of these groups consisted of patients with different stages of multiple sclerosis: those with a first isolated attack, those with the relapsing-remitting form where symptoms come and go, and those with the two progressive forms where symptoms slowly worsen without recovery. The other two groups were people with other neurological conditions and healthy volunteers with no neurological issues. The scientists collected stool samples to count the types of bacteria present and took blood samples to measure the levels of two specific microRNAs, miR-155 and miR-20a, which are known to be involved in inflammation. They wanted to see if the gut bacteria and these genetic markers changed in a specific way as the disease progressed from its early stages to its most severe forms.
The results showed that the gut environment and the genetic switches were indeed different depending on the stage of the disease, with the most dramatic changes appearing in the progressive form of the disease. In patients with the most advanced, progressive stage, the researchers found a significant drop in the numbers of beneficial bacteria that help keep the gut healthy and reduce inflammation. At the same time, there was an increase in bacteria often associated with inflammation. This shift was accompanied by a change in the blood levels of the two microRNAs. The level of miR-155, which tends to promote inflammation, was higher in patients with the disease compared to healthy people. Conversely, the level of miR-20a, which helps calm the immune system, was lower in the patients, and it was lowest in those with the progressive form of the disease.
When the researchers looked at how well these markers could tell the groups apart, they found that certain bacteria were exceptionally good at identifying the progressive form of the disease. One specific group of bacteria, known as Bacteroidetes, was so low in the progressive patients that it could distinguish them from healthy people with near-perfect accuracy. Similarly, the level of miR-20a was very effective at separating patients with the relapsing-remitting form and the primary progressive form from healthy controls. The study also revealed a clear connection between the bacteria and the genetic markers. The beneficial bacteria that were low in the patients were linked to higher levels of the calming miR-20a, while the inflammatory bacteria were linked to higher levels of the pro-inflammatory miR-155. This suggests that the state of the gut bacteria might be influencing how these genetic switches are set, creating a cycle that could drive the disease forward.
Perhaps most importantly, the researchers found that looking at the bacteria and the microRNAs together provided a much clearer picture than looking at either one alone. By combining the data from the gut bacteria and the blood markers, they could create a profile that distinguished between the different types of multiple sclerosis with extremely high accuracy. For example, a specific combination of Firmicutes and Bacteroidetes separated patients with the relapsing-remitting form from those with the secondary progressive form with an accuracy score (AUC) of 0.9881. This suggests that the disease is not just a single condition but a collection of different biological states, each with its own unique signature of gut bacteria and genetic activity.
While these findings offer a promising new way to understand and potentially diagnose the different stages of multiple sclerosis, the researchers are careful to note that this is a snapshot in time. The study was conducted on a specific group of people in one region, and the results need to be tested in larger groups over a longer period to confirm that these changes are truly causing the disease progression rather than just being a side effect. The authors suggest that future research should explore whether changing the gut bacteria through diet or other means could alter these genetic markers and slow down the disease. For now, this work provides a strong foundation for the idea that the gut and the immune system are deeply connected in multiple sclerosis, offering new clues for how to tell the different forms of the disease apart and perhaps how to treat them more effectively in the future.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.